Eli Lilly, Nordisk seek expanded pleading bar in US case over GLP-1 drugs, Texas, Louisiana say
( July 21, 2026, 18:14 GMT | Official Statement) -- MLex Summary: The attorneys general for Texas and Louisiana told a US federal judge that accepting Eli Lilly and Novo Nordisk’s motion to dismiss antitrust claims over GLP-1 drugs would heighten the pleading bar for federal antitrust claims to the detriment of consumers. The attorneys general filed a brief arguing that a relevant market can be defined from the perspective of a distinct group of consumers, and plaintiffs can allege substantial foreclosure based on qualitative factors. The case accuses the companies of entering into exclusive agreements with telehealth platforms to block those platforms from selling Strive’s competing compounded GLP-1 drugs.See attached file....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.